Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy

Journal for ImmunoTherapy of Cancer

Volumn 4, Issue 1, 2016, Pages

  Koelzer, Viktor H ^a,b   Buser, Tobias ^c   Willi, Niels ^a   Rothschild, Sacha I ^c   Wicki, Andreas ^c   Schiller, Peter ^a   Cathomas, Gieri ^a   Zippelius, Alfred ^c   Mertz, Kirsten D ^a  

^a Kantonsspital Liestal   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Autoimmunity; Drug eruption; Grover's disease; Immune checkpoint inhibitors; Immunotherapy; Ipilimumab; Melanoma; Transient acantholytic dermatosis

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; IPILIMUMAB; PROGRAMMED DEATH 1 RECEPTOR; STEROID;

ACANTHOLYTIC DYSKERATOSIS; AGED; APHASIA; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG ERUPTION; ERYTHEMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NEOPLASM; PAPULOVESICULAR RASH; PRIORITY JOURNAL; PRURITUS; SEIZURE; SKIN BIOPSY; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; THORACOSCOPY; TOXIC EPIDERMAL NECROLYSIS; TRANSIENT ACANTHOLYTIC DERMATOSIS;

EID: 84997693823     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-016-0151-z     Document Type: Article

References (18)

1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-30. doi: 10.1056/NEJMoa1412082.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. doi: 10.1056/NEJMoa1003466.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16. doi: 10.1056/NEJMoa1103782.
4. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375-91. doi: 10.1093/annonc/mdv383.
5. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691-7. doi: 10.1200/JCO.2012.41.6750.
6. Lacouture ME, Wolchok JD, Yosipovitch G, Kahler KC, Busam KJ, Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol. 2014;71(1):161-9. doi: 10.1016/j.jaad.2014.02.035.
7. Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo). 2013;2013:857519. doi:10.1155/2013/857519.
8. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008;105(8):3005-10. doi: 10.1073/pnas.0712237105.
9. Weaver J, Bergfeld WF. Grover disease (transient acantholytic dermatosis). Arch Pathol Lab Med. 2009;133(9):1490-4. doi: 10.1043/1543-2165-133.9.1490.
10. Desch JK, Smoller BR. The spectrum of cutaneous disease in leukemias. J Cutan Pathol. 1993;20(5):407-10.
11. Davis MD, Dinneen AM, Landa N, Gibson LE. Grover's disease: clinicopathologic review of 72 cases. Mayo Clin Proc. 1999;74(3):229-34. doi: 10.4065/74.3.229.
12. Zvulunov A, Grunwald MH, Avinoach I, Halevy S. Transient acantholytic dermatosis (Grover's disease) in a patient with progressive systemic sclerosis treated with D-penicillamine. Int J Dermatol. 1997;36(6):476-7.
13. Mahler SJ, De Villez RL, Pulitzer DR. Transient acantholytic dermatosis induced by recombinant human interleukin 4. J Am Acad Dermatol. 1993;29(2 Pt 1):206-9.
14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
15. Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012;67(6):1265-72. doi: 10.1016/j.jaad.2012.04.008.
16. Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012;167(5):1153-60. doi: 10.1111/j.1365-2133.2012.11155.x.
17. Carlos G, Anforth R, Chou S, Clements A, Fernandez-Penas P. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015;25(3):265-8. doi: 10.1097/CMR.0000000000000155.
18. Munoz J, Guillot B, Girard C, Dereure O, Du-Thanh A. First report of ipilimumab-induced Grover disease. Br J Dermatol. 2014;171(5):1236-7. doi: 10.1111/bjd.13058.